News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Vetigenics’ Treats its First Canine Cancer Patient
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
IND Clearance Achieved by Cabaletta Bio
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
PCI Hosts IvyTech 2023
The goal was to discuss various topics related to technology commercialization, startup company formation, and building relationships between academia and the commercial sector.
Philadelphia region designated a federal tech hub for life sciences
The Philadelphia region has been designated as a federal innovation and technology hub, allowing it to compete for a grant of up to $75 million to advance its life sciences industry.
Emily Whitehead, the first child to be cured of cancer with Penn-invented CAR-T therapy, is now a freshman at Penn
From American Sign Language to English to nature photography, Emily has a wide range of interests she intends to explore in her studies.
Penn Hosts IvyTech 2023 – Event Recap
Last week, PCI hosted IvyTech, an annual conference that brings together technology transfer professionals to discuss the future of research, commercialization, and intellectual property.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.
Penn Faculty Discover An Innovative Potential Treatment for Tooth Decay
In search of a more effective treatment, the research team employed a combination of ferumoxytol (Fer) and stannous fluoride (SnF2) to fight tooth decay.
FloBio Receives the FDA’s Breakthrough Device Designation for its Bleeding Risk Diagnostic Test
FloBio's test determines blood clotting status and identifies whether a patient is on popular blood thinners called Direct Oral Anticoagulants (DOACs).